Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-30

Clinical Trial Update: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing inhaled BI 1744 CL with inhaled tiotropium bromide in chronic obstructive pulmonary disease was completed, with results on 24-hour spiro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 1744 CL
  • Tiotropium bromide (Spiriva) (tiotropium bromide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-06-30